• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cosmos Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    9/29/25 9:59:07 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care
    Get the next $COSM alert in real time by email
    cosm_8k.htm
    0001474167false00014741672025-09-292025-09-29iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) September 29, 2025

     

    COSMOS HEALTH INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada

     

    000-54436

     

    27-0611758

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    5 Agiou Georgiou, Pilea, Thessaloniki, Greece

     

    55438

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant’s telephone number, including area code (312) 865-0026

     

    N/A

    (Former name or former address, if changed since last report.)

     

    Title of Each Class

     

    Trading Symbol

     

    Name of Each Exchange On Which Registered

    Common Stock, $.001 par value

     

    COSM

     

    Nasdaq Capital Market

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 7.01 Regulation FD Disclosure

     

    On September 29, 2025, Cosmos Health Inc. (the “Company”) made available its Chief Executive Officer's annual letter to shareholders for the year ended December 31, 2024, dated as of September 29, 2025. The Chief Executive Officer's annual letter contains information that may be of interest to investors. A copy of the Chief Executive Officer's annual letter is attached hereto as Exhibit 99.1 and incorporated herein by reference.

     

    FORWARD-LOOKING STATEMENTS

     

    Certain statements contained herein constitute forward-looking statements as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include, but are not limited to, statements relating to the Company's anticipated strategic plans and related outcomes. Forward-looking statements are not guarantees of future performance, and there can be no assurance that the Company will, or will have the ability to, execute on its anticipated strategic plans or will realize the expected outcome of its plans as anticipated or at all. They represent our intentions, plans, expectations and beliefs and are subject to numerous assumptions, risks and uncertainties. Our future results, financial condition and business may differ materially from those expressed in these forward-looking statements. You can identify many of these statements by words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “would,” “may” or other similar expressions in the Company's Annual Report on Form 10-K. For a discussion of factors that could materially affect the outcome of our forward-looking statements, see “Risk Factors” in Part I, Item 1A, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K  and the other documents filed by the Company with the SEC and any amendments thereto, including the information contained in the attached letter. We do not undertake any obligation to release publicly any revisions to our forward-looking statements to reflect events or circumstances occurring after the date of this Current Report on Form 8-K.

     

    In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of Section 18, nor shall it be deemed incorporated by reference into any filing of the Company or the Operating Partnership under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Item

     

    Description

    99.1

     

    Chief Executive Officer’s Letter, dated September 29, 2025.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

    2

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    COSMOS HEALTH INC.

     

     

     

     

    Date: September 29, 2025

    By:

    /s/ George Terzis

    George Terzis

     

    Chief Financial Officer

     

     

     

    3

      

    Get the next $COSM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COSM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/27/25 9:33:43 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/23/25 12:18:06 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/22/25 10:33:17 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    SEC Filings

    View All

    Cosmos Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cosmos Health Inc. (0001474167) (Filer)

    10/17/25 11:09:20 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Cosmos Health Inc. (0001474167) (Filer)

    10/6/25 4:20:37 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Cosmos Health Inc. (0001474167) (Filer)

    10/1/25 6:02:51 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/27/25 9:33:43 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/23/25 12:18:06 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/22/25 10:33:17 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million

    CHICAGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has acquired an additional $200,000 worth of Ethereum (ETH), bringing the Company's total investment in ETH to $2 million. This purchase was executed under Cosmos Health's previously announced $300 million digital assets facility, which underpins the Company's strategy to broaden and strengthen its portfolio through targeted digital asset investments. Greg Siokas, CEO of Cosmos Health, stated: "Reaching the $2 million milestone in our Ethereum investment marks another important step in our dig

    10/21/25 12:10:52 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement

    CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that on October 15, 2025, it received written notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the "Listing Rule"). In the Notice, Nasdaq stated that for the last 18 consecutive business days, from September 22, 2025, to October 15, 2025, the closing bid price of the Company's common stock has been at or above $1.00 per share. Accordingly, the

    10/16/25 8:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million

    CHICAGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has purchased an additional $300,000 worth of Ethereum (ETH), increasing its total investment in ETH to $1.8 million. This latest purchase was made under Cosmos Health's previously announced $300 million digital assets facility, which supports the Company's ongoing strategy to diversify its portfolio through strategic digital asset investments. Greg Siokas, CEO of Cosmos Health, stated: "We have continued to increase our Ethereum holdings following last week's purchase, bringing our total inve

    10/13/25 2:05:46 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Financials

    Live finance-specific insights

    View All

    Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

    CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

    4/30/25 12:50:09 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

    CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

    1/21/25 3:00:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Issues Letter to Shareholders

    CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

    11/12/24 12:01:41 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

    CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

    4/16/25 12:45:15 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

    CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc

    12/26/24 1:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

    THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded

    11/21/23 9:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Cosmos Health Inc.

    SC 13G - Cosmos Health Inc. (0001474167) (Subject)

    2/14/24 3:33:29 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

    SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)

    7/25/23 4:06:11 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care